Evidence map›Paper›PMID 37311045›Full record

ArticleStem cells translational medicine2023

Mesenchymal Stem Cell-Extracellular Vesicle Therapy for Stroke: Scalable Production and Imaging Biomarker Studies.

Jeong Pyo Son, Eun Hee Kim, Eun Kyoung Shin, Dong Hee Kim, Ji Hee Sung, Mi Jeong Oh, Jae Min Cha, Michael Chopp, Oh Young Bang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jeong Pyo SonDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea.
Eun Hee KimStem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea.
Eun Kyoung ShinStem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea.
Dong Hee KimDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea.
Ji Hee SungStem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea.
Mi Jeong OhStem Cell and Regenerative Medicine Institute, Samsung Medical Center, Seoul, South Korea.
Jae Min Cha3D Stem Cell Bioprocessing Laboratory, Department of Mechatronics, Incheon National University, Incheon, South Korea.
Michael ChoppDepartment of Neurology, Henry Ford Health System, Detroit, MI, USA.
Oh Young BangDepartment of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea.ORCID 0000-0002-7962-8751
Samsung Medical Center · KRSamsung (South Korea) · KRHenry Ford Health System · USIncheon National University · KRKorea Atomic Energy Research Institute · KR

Funding

Ministry of Trade, Industry & EnergyTechnology Innovation Program 1415174804
6 · The paper itself

Abstract

A major clinical hurdle to translate MSC-derived extracellular vesicles (EVs) is the lack of a method to scale-up the production of EVs with customized therapeutic properties. In this study, we tested whether EV production by a scalable 3D-bioprocessing method is feasible and improves neuroplasticity in animal models of stroke using MRI study. MSCs were cultured in a 3D-spheroid using a micro-patterned well. The EVs were isolated with filter and tangential flow filtration and characterized using electron microscopy, nanoparticle tracking analysis, and small RNA sequencing. Compared to conventional 2D culture, the production-reproduction of EVs (the number/size of particles and EV purity) obtained from 3D platform were more consistent among different lots from the same donor and among different donors. Several microRNAs with molecular functions associated with neurogenesis were upregulated in EVs obtained from 3D platform. EVs induced both neurogenesis and neuritogenesis via microRNAs (especially, miR-27a-3p and miR-132-3p)-mediated actions. EV therapy improved functional recovery on behavioral tests and reduced infarct volume on MRI in stroke models. The dose of MSC-EVs of 1/30 cell dose had similar therapeutic effects. In addition, the EV group had better anatomical and functional connectivity on diffusion tensor imaging and resting-state functional MRI in a mouse stroke model. This study shows that clinical-scale MSC-EV therapeutics are feasible, cost-effective, and improve functional recovery following experimental stroke, with a likely contribution from enhanced neurogenesis and neuroplasticity.

Indexed as

Extracellular VesiclesMesenchymal Stem CellsMicroRNAsStrokeAnimalsBiomarkersDiffusion Tensor ImagingMiceBiomarkersMicroRNAsextracellular vesiclesmagnetic resonance imagingneurogenesisstem cellsstroke

Identifiers

PMID37311045
PMCPMC10346399
OpenAlexW4380538280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.